AZTherapies

Az Therapies

Pharmaceuticals, 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States, 11-50 Employees

aztherapies.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is AZTHERAPIES

AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approa...

Read More

map
  • 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States Headquarters: 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States
  • 2011 Date Founded: 2011
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AZTHERAPIES

AZTherapies Org Chart and Mapping

Employees

Katie Barrett

Associate Director of Clinical Operations

Breana Loreaux

Technical Operations Manager

David Brazier

Senior Director , Clinical Operations

Levi Watkin

Research Immunologist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AZTherapies

Answer: AZTherapies's headquarters are located at 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States

Answer: AZTherapies's phone number is 61********

Answer: AZTherapies's official website is https://aztherapies.com

Answer: AZTherapies's revenue is $5 Million to $10 Million

Answer: AZTherapies's SIC: 2834

Answer: AZTherapies's NAICS: 561110

Answer: AZTherapies has 11-50 employees

Answer: AZTherapies is in Pharmaceuticals

Answer: AZTherapies contact info: Phone number: 61******** Website: https://aztherapies.com

Answer: AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approach that recognizes neuro-inflammation as a root cause of neuro-degeneration, leveraging the ability of cromolyn, a small molecule with a well-characterized safety profile, to shift the brains innate immune cells from a pro-inflammatory to neuroprotective state. We are advancing a pipeline of candidates in Alzheimer's Disease, amyotrophic lateral sclerosis (ALS) and post-ischemic stroke cognitive impairment.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access